Sai Life Sciences Ltd (SAILIFE) — shareholding pattern, promoter holding, financials and share price
About Sai Life Sciences Ltd (SAILIFE)
Sai Life Sciences Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as SAILIFE and on the BSE under scrip code 544306. Its ISIN is INE570L01029.
Incorporated in 1999, Sai Life Sciences Ltd carries out contract research and manufacturing activities for customers engaged in pharmaceutical and bio technology industries [1]
Sai Life Sciences is an integrated CRDMO providing end-to-end discovery, development and commercial manufacturing services to global pharmaceutical and biotechnology innovators, operating discovery and R&D labs in Boston and Manchester plus large GMP manufacturing and R&D campuses in India.
Q3 FY26 revenue was ₹556 crore (+27% YoY) and 9MFY26 revenue reached ₹1,590 crore (+43% YoY); EBITDA margin expanded to 34% in Q3 and 30% for 9MFY26, driven by operating leverage on employee costs and improved material margins.
Listed peers in Pharmaceuticals: Wockhardt Ltd, Acutaas Chemicals Ltd, Neuland Laboratories Ltd, Rubicon Research Ltd, Piramal Pharma Ltd, Granules India Ltd.
Valuation & Returns
10 Jul 2026At ₹1,264.15 a share on 10 Jul 2026, Sai Life Sciences Ltd (SAILIFE) was valued at a price-to-earnings ratio of 76.91x against an industry P/E of 36.41x and a price-to-book of 12.61x on a book value of ₹100.26 per share as of Mar 2025. Solomo computes return on equity of 16.39% and return on capital employed of 20.37% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 76.91x
- Industry P/E
- 36.41x
- P/B
- 12.61x
- EPS (TTM)
- ₹16.44
- Book value / share
- ₹100.26
- ROE
- 16.39%
- ROCE
- 20.37%
- ROA
- 11.04%
- Debt / equity
- 0.17x
- Dividend yield
- 0%
- EBITDA margin
- 30.66%
- 52-week range
- ₹776.2 – ₹1,286.2
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Sai Life Sciences Ltd (SAILIFE) reported revenue of ₹2,192 crore, net profit of ₹349 crore and earnings per share of ₹16.48. That compares with revenue of ₹1,695 crore and net profit of ₹170 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹602 crore and net profit ₹104 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 870 | 1,217 | 1,465 | 1,695 | 2,192 |
| Net profit (₹ cr) | 6 | 10 | 83 | 170 | 349 |
| EPS (₹) | - | - | - | 8.16 | 16.48 |
| Measure | 5Y | 3Y | 1Y |
|---|---|---|---|
| Sales growth | 17.75% | 24.99% | 15.66% |
| Profit growth | 16.70% | 122.81% | 105.45% |
| Stock price CAGR | - | - | 59% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 34.53% of Sai Life Sciences Ltd (SAILIFE) (down 0.08 pp QoQ), foreign institutional investors (FII) hold 19.65% and domestic institutional investors (DII) hold 32.71%. Market capitalisation was ₹26,836 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Dec 2024.
Largest disclosed public shareholders in Jun 2026: INVESCO INDIA MANUFACTURING FUND 7.44%, NIPPON LIFE INDIA TRUSTEE LTD A/C NIPPON INDIA MNC 6.66%, AXIS MUTUAL FUND TRUSTEE LIMITED A/C AXIS MUTUAL F 2.9%, ADITYA BIRLA SUN LIFE TRUSTEE PRIVATE LIMITED A/C 2.76%, SMALLCAP WORLD FUND, INC 2.57%, HSBC MUTUAL FUND - HSBC AGGRESSIVE HYBRID FUND 1.86%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 34.53% | - | 19.65% | 32.71% | 65.47% |
| Mar 2026 | 34.61% | - | 21.17% | 31.54% | 65.39% |
| Dec 2025 | 34.7% | - | 21.4% | 31.41% | 65.3% |
| Sep 2025 | 34.94% | - | 22.5% | 29.91% | 65.06% |
| Jun 2025 | 35.15% | - | 14.58% | 21.64% | 64.85% |
| Mar 2025 | 35.17% | 2.7% | 12.36% | 13.26% | 64.83% |
| Dec 2024 | 35.24% | 2.7% | 11.72% | 11.95% | 64.76% |